Uncontrolled Moderate to Severe Eosinophilic Asthma research hub

A Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long Term Safety and Tolerability of KT-621 in Participants With Asthma Previously Enrolled in a KT-621 Asthma Study

This study looks at the long-term safety of a new medicine called KT-621 for adults with moderate to severe eosinophilic asthma. It is an extension study for people who already took part in an earlier KT-621 trial, checking how well the body tolerates the treatment over 52 weeks.